Ignite Creation Date:
2024-05-06 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 12:01 PM
Study NCT ID:
NCT02751931
Status:
COMPLETED
Last Update Posted:
2022-10-20
First Post:
2016-04-22
Brief Title:
Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity
Sponsor:
Astellas Pharma Europe BV
Organization:
Astellas Pharma Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-06-17
Start Date Type:
ACTUAL
Primary Completion Date:
2018-11-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-05-06
Completion Date Type:
ACTUAL
First Submit Date:
2016-04-22
First Submit QC Date:
April 22 2016
Study First Post Date:
2016-04-26
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2020-05-12
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
2019-10-31
Disp First Submit QC Date:
October 31 2019
Disp First Post Date:
2019-11-06
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2022-09-21
Last Update Post Date:
2022-10-20
Last Update Post Date Type:
ACTUAL